Psychiatric Manifestations of Voriconazole
Voriconazole commonly causes visual and auditory hallucinations, which are reversible neuropsychiatric adverse effects that occur in approximately 2-3% of patients and are often associated with higher drug concentrations. 1
Primary Psychiatric Manifestations
The most clinically significant psychiatric effects include:
Hallucinations (visual and auditory): Reported in 2.4-2.8% of patients in therapeutic trials 1. These can present as vivid visual hallucinations, auditory hallucinations, or both 2, 3, 4, 5
Delirium and altered consciousness: Patients may develop confusion, disorientation, and delirium that can be misdiagnosed as postoperative delirium or other causes of encephalopathy 2, 4
Disorders of consciousness: Including slow response, restlessness, and agitation 4
Key Clinical Characteristics
Timing and Onset
Psychiatric symptoms typically appear within 1 week of initiating voriconazole therapy 3 and can occur acutely after treatment begins 5.
Concentration-Dependent Toxicity
Hallucinations and neuropsychiatric symptoms are strongly associated with elevated voriconazole trough concentrations, particularly levels >5.0 mg/L 2, 3. The FDA label confirms that toxicity is more common with higher drug levels, though not entirely predictable based on concentration alone 1.
Reversibility
All psychiatric manifestations are reversible upon discontinuation or dose reduction of voriconazole, typically resolving within 4 days of stopping the drug 2, 3, 5.
Mechanism and Risk Factors
The mechanism underlying voriconazole-induced hallucinations remains incompletely understood, though recent evidence suggests dopaminergic modulation may play a role—concomitant use with dopaminergic medications like levodopa significantly increases the risk of visual hallucinations (ROR = 12.3) 6.
Asian populations warrant special attention due to higher prevalence of CYP2C19 poor metabolizers, which leads to reduced voriconazole clearance and increased risk of adverse events 3.
Neurologic Context from Guidelines
The IDSA guidelines 7 emphasize that:
- Reversible central and peripheral neurologic symptoms and hallucinations occur with significant variability
- These symptoms may be confused with other CNS dysfunction etiologies including posterior reversible leukoencephalopathy syndrome or calcineurin inhibitor toxicity
- Voriconazole concentrations are a predictor of CNS neurotoxicity, which is reversible
Clinical Management Algorithm
Recognition: Consider voriconazole as the cause when hallucinations, delirium, or altered consciousness develop within days to weeks of starting therapy
Immediate assessment:
- Measure voriconazole trough concentration (target therapeutic range 1.0-5.5 mg/L; toxicity risk increases >5.0 mg/L)
- Rule out alternative causes (metabolic derangements, other medications, CNS infection)
Intervention:
Monitoring: Serial therapeutic drug monitoring is crucial, especially in Asian patients and those on interacting medications 3, 8
Critical Pitfalls to Avoid
Do not misattribute symptoms to postoperative delirium, ICU psychosis, or other causes without first checking voriconazole levels and considering temporal relationship 2
Do not continue voriconazole at the same dose when psychiatric symptoms emerge—this risks progression to more severe neurotoxicity
Route of administration does not influence frequency of these adverse events—both IV and oral formulations carry equal risk 3, 5
Be aware that visual disturbances (photopsia, altered color perception) occur in ~21% of patients 1 and may accompany or precede frank hallucinations